Orion Portfolio Solutions LLC Reduces Holdings in Solventum Co. (NYSE:SOLV)

Orion Portfolio Solutions LLC lowered its position in Solventum Co. (NYSE:SOLV) by 3.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 18,317 shares of the company’s stock after selling 561 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Solventum were worth $1,210,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SOLV. denkapparat Operations GmbH purchased a new position in shares of Solventum during the 4th quarter valued at approximately $212,000. Pictet Asset Management Holding SA raised its holdings in Solventum by 16.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 87,028 shares of the company’s stock valued at $5,749,000 after acquiring an additional 12,437 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Solventum by 0.7% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 44,741 shares of the company’s stock valued at $2,956,000 after acquiring an additional 300 shares during the last quarter. New Age Alpha Advisors LLC acquired a new position in Solventum during the 4th quarter worth $92,000. Finally, Kiltearn Partners LLP increased its position in shares of Solventum by 80.6% in the 4th quarter. Kiltearn Partners LLP now owns 73,500 shares of the company’s stock worth $4,855,000 after purchasing an additional 32,800 shares during the last quarter.

Solventum Price Performance

Shares of NYSE SOLV opened at $66.22 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market capitalization of $11.45 billion and a PE ratio of 24.08. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The business’s fifty day moving average price is $75.42 and its two-hundred day moving average price is $71.95.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SOLV shares. The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Piper Sandler lifted their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Bank of America boosted their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.